GeneIII key facts
as of Oct 2026- Developer and manufacturer of synthetic biotechnology created to provide customers with better products and services.
- GeneIII is valued at approximately $55.5M as of Oct 2026 (last reported valuation).
- It has raised $22.1M; the latest was Early Stage VC in May 2025.
- Notable investors include Huayi Capital, CITIC Investment Holdings, JIF Capital, Xinxiang Tuoxin.
- Status: Privately Held (backing).
GeneIII's last reported valuation, Jul 2023. Nothing priced has surfaced since.
- ·Watch GeneIII: the Monday email on marks, rounds and moves
GeneIII funding rounds
No funding rounds for GeneIII are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs GeneIII
4GeneIII valuation
GeneIII's last reported valuation was $55.5 million in Jul 2023. No priced round, secondary trade or fund mark has surfaced since.
GeneIII investors
4 investors are on record for GeneIII, including Huayi Capital, CITIC Investment Holdings, JIF Capital and Xinxiang Tuoxin.
About GeneIII
Developer and manufacturer of synthetic biotechnology created to provide customers with better products and services. The company focuses on the field of great health and beauty, its products are mainly oriented to the big health and big beauty markets, enabling its clients in the dietary supplements and functional skin care industries to meet the need of raw material demand.
- Sector
- Materials and Resources
- HQ
- Nanjing, China
- Founded
- 2021
- Website
- geneiii.com.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.